Polypoidal choroidal vasculopathy (PCV) Polypoidal choroidal vasculopathy PCV Bevacizumab Bevacizumab monotherapy Avastin
Conditions
Interventions
Patients who exhibited an absence of subretinal fluid (SRF), intraretinal fluid (IRF), intraretinal cysts (IRC), or a reduction in central retinal thickness (CRT) greater than 75% of the baseline valu
Treatment,Treatment
Good responders,Poor responders
Sponsors
None
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with a diagnosis of PCV defined by the EVEREST diagnostic criteria who met the following inclusion criteria were enrolled in the study: EVEREST diagnostic criteria of PCV: Early subretinal ICGA hyperfluorescence (appearing within the first 5 min of ICG dye injection) and at least one of the following diagnostic criteria 1. Nodular appearance of the polyp on stereoscopic viewing 2. Hypofluorescent halo around the nodule 3. Abnormal vascular channel(s) supplying the polyps 4. Pulsatile filling of polyps 5. Orange subretinal nodules corresponding to the hyperfluorescent area on ICGA 6. Massive submacular hemorrhage (defined as size of hemorrhage of at least 4 disc areas) Additional inclusion criteria were as follows: 1. Age 18 years or older. 2. Best corrected visual acuity (BCVA) equal to or worse than 20/32 with the presence of serosanguinous maculopathy involving the macula (within a 5500 um diameter around the fovea). 3. Treated with a 3-month consecutive loading phase of intravitreal bevacizumab (1.25 mg/0.05 ml) per injection. 4. Baseline imaging of optical coherence tomography (OCT), fundus photography, and indocyanine green angiography (ICGA) available.
Exclusion criteria
Exclusion criteria: 1. Had received previous treatments with intravitreal anti-VEGF, verteporfin photodynamic therapy (PDT), focal laser photocoagulation, or pneumatic displacement of subretinal blood. 2. Presented with massive subretinal hemorrhage that obscured ICGA interpretation. 3. Had a history of pathological myopia, retinal detachment, macular hole, or uncontrolled glaucoma. 4. Had coexisting conditions that could cause macular edema, such as diabetic macular edema, posterior uveitis, or retinal vein occlusion. 5. Had undergone intraocular surgery (except uncomplicated cataract extraction with intraocular lens implantation) within 60 days before the first visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Baseline Predictive Factors at 3 months after three monthly intravitreal bevacizumab injections Patient characteristics, Ocular examinations, Fundus Photography Findings, OCT Findings, ICG Angiography Findings | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of bevacizumab at 12 months after three monthly intravitreal bevacizumab injections Visual acuity (BCVA), central subfoveal thickness (CST), Subretinal fluid (SRF) height,Treatment regimen Over 12 months after three monthly intravitreal bevacizumab injections Total injection, Maximum treatment interval in the first year (weeks), Derferment of injection, Recurrence after deferment, Mean recurrence time (weeks) | — |
Countries
Thailand
Contacts
Public ContactChinnapat Montrisuksirikun
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed